IDEA: Intervention to prevent depressive symptoms and promote well-being in early stage dementia

Conditions

Early-stage dementia Mental and Behavioural Disorders Dementia in Alzheimer disease

Vasiliki Orgeta, Remco Tuijt, Phuong Leung, Elisabet Solé Verdaguer, Rebecca L. Gould et al. (7 authors)

Journal of Alzheimer s Disease2019-10-0818 citations

10.3233/jad-190696

IDEA intervention to prevent depressive symptoms and promote well-being in early-stage dementia: protocol for a randomised controlled feasibility study

Remco Tuijt, Gill Livingston, Rebecca L. Gould, Rebecca Jones, Elisabet Solé Verdaguer et al. (6 authors)

BMJ Open2018-02-013 citations

10.1136/bmjopen-2017-021074

Interventions

Participants will be randomly allocated to two treatment arms - treatment as usual or treatment as usual plus the Behavioral Activation intervention. The intervention is an 8-session

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. People with mild dementia (MMSE = 20) 2. People with dementia who have received a diagnosis in the last 6 months 3. Living in the community 4. Available family carer who can assist the person with dementia in the intervention and can act as an informant (weekly contact)

Exclusion criteria

Exclusion criteria: People at risk of suicide (clinicians’ judgement)

Design outcomes

Primary

Measure	Time frame
1. Number of eligible participants that consent to the study, and number of those finding the intervention acceptable using 95 Confidence Intervals % 2. Number of dyads recruited per month and any barriers or facilitators to recruitment 3. Follow-up rates and number completing each outcome measure proposed for the main trial 4. Number of sessions attended 5. Standard deviations and correlations between repeated-measurements Outcomes will be measured at 4 and 8 months.	—

Measure

Time frame

1. Number of eligible participants that consent to the study, and number of those finding the intervention acceptable using 95 Confidence Intervals % 2. Number of dyads recruited per month and any barriers or facilitators to recruitment 3. Follow-up rates and number completing each outcome measure proposed for the main trial 4. Number of sessions attended 5. Standard deviations and correlations between repeated-measurements Outcomes will be measured at 4 and 8 months.

—

Secondary

Measure	Time frame
People with dementia: 1. Depressive symptoms - Cornell Scale for Depression in Dementia (CSDD) 2. Self-rated and carer-rated dementia-specific quality of life for the person with dementia – DEMQOL 3. Neuropsychiatric symptoms - Neuropsychiatric Inventory (NPI) 4. Health services utilisation - Client Service Receipt Inventory (CSRI) Carers: 1. Carers’ mental health - Hospital and Anxiety Depression Scale (HADS) 2. Carers' quality of life - EuroQoL EQ-5D (EQ-5D) and the Short Form-12 Health Survey (SF-12) Outcomes will be measured at 4 and 8 months.	—

Measure

Time frame

People with dementia: 1. Depressive symptoms - Cornell Scale for Depression in Dementia (CSDD) 2. Self-rated and carer-rated dementia-specific quality of life for the person with dementia – DEMQOL 3. Neuropsychiatric symptoms - Neuropsychiatric Inventory (NPI) 4. Health services utilisation - Client Service Receipt Inventory (CSRI) Carers: 1. Carers’ mental health - Hospital and Anxiety Depression Scale (HADS) 2. Carers' quality of life - EuroQoL EQ-5D (EQ-5D) and the Short Form-12 Health Survey (SF-12) Outcomes will be measured at 4 and 8 months.

—

Countries

United Kingdom

Contacts

Public ContactVasiliki Orgeta

v.orgeta@ucl.ac.uk02076799294

Outcome results

None listed